The patent covers progesterone (or PdG) testing via urine test, a method for identifying the fertile window by testing PdG and other hormones, and a multi-hormone test that includes testing for PdG and one or more other hormones associated with the menstrual cycle. Prior to Proov's offerings - the only FDA-Cleared urine PdG test - no diagnostic test could confirm successful ovulation. Proov's fourth patent adds to Proov's industry-leading patent portfolio, related to the testing of PdG in urine in women. Proov continues to lead the development of at-home hormone testing technologies to empower women, and has many additional related technologies covered by pending patent applications. Don't just predict ovulation, Proov it!

Source: Forbes January 30, 2023 20:06 UTC